Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1988 Apr;6(1):51-6.
doi: 10.1007/BF00170781.

Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck With Isotretinoin: A Phase II Randomized Trial

Affiliations
Free article
Clinical Trial

Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck With Isotretinoin: A Phase II Randomized Trial

S M Lippman et al. Invest New Drugs. .
Free article

Abstract

Retinoids, the analogs of vitamin A, are active in vitro and in vivo against squamous cell carcinoma in animals and against certain epithelial precancers and cancers in humans. These data led us to design a prospective, multi-institutional, randomized phase II trial of isotretinoin in advanced head and neck squamous cell carcinoma. We randomly assigned 40 patients to receive isotretinoin or methotrexate, the best-studied and most active single agent for this disease. Overall, the study patients had extremely poor prognoses, i.e., low performance statuses and recurring disease after surgery and/or irradiation. Three objective responses (16%), including one complete response, occurred in the 19 evaluable isotretinoin-treated patients. Only one minor response (5%) occurred in the methotrexate-treated group. Toxicity occurred with both drugs, but was manageable and never life threatening in the retinoid group. These results and the established activity of retinoids in oral leukoplakia (a precursor of head and neck cancer) indicate the need for further study of this class of drugs in head and neck cancer.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles

References

    1. N Engl J Med. 1983 Jan 13;308(2):75-9 - PubMed
    1. Lancet. 1983 Jun 18;1(8338):1345-7 - PubMed
    1. Ann Intern Med. 1987 Oct;107(4):499-502 - PubMed
    1. Am J Surg. 1983 Oct;146(4):466-70 - PubMed
    1. J Am Acad Dermatol. 1986 Oct;15(4 Pt 2):756-64 - PubMed

Publication types

Feedback